Investors had been awaiting an update on voxelotor with trepidation, but a lenient FDA has lit up the company’s Ash.
Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.
Vertex is due the first pivotal data on its cystic fibrosis triplets, while Global Blood Therapeutics will soon find out whether it can take a shortcut on voxelotor’s…
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Global Blood punching above its weight in sickle cell as 2022 sales forecasts for voxelotor hit $529m in 2022.
A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.